Yan Leyfman: New study challenges the 8-week driving restriction for patients receiving CAR-T therapy for MM
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Rahul Banerjee et al. published in Blood Advances:
“Are Driving Restrictions After CAR-T Therapy Too Long?
New study in Blood Advances led by Rahul Banerjee and Gurbakhash Kaur challenges the 8-week driving restriction for patients receiving CAR-T therapy for multiple myeloma (MM). Researchers analyzed 586 patients and found that only 1% experienced driving-relevant adverse events (drAEs) between Weeks 5-8.
Key Findings:
- The majority of drAEs (e.g., CRS, ICANS) occur within the first 2 weeks.
- No seizures were reported in Weeks 5-8, the main concern behind restrictions.
- 77% of oncologists disagreed with extending driving bans beyond Week 4.
Implication:
This study suggests individualized driving restrictions after Week 4, rather than a universal 8-week ban, to reduce unnecessary burdens on patients.
Should post-CAR-T driving restrictions be re-evaluated?”
Authors: Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Thomas Martin, Peter Voorhees, Larry Anderson, Jr., Andrew Cowan, Gurbakhash Kaur et al.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023